PSI Advisors’s Alaunos Therapeutics TCRT Stock Holding History

PSI Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6	Closed	-$9	–	623
2025 Q1	$9	Hold	6	–	–	﹤0.01%	751
2024 Q4	$11	Hold	6	–	–	﹤0.01%	885
2024 Q3	$19	Sell	6 -1	-14%	-$4	﹤0.01%	885
2024 Q2	$46	Hold	7	–	–	﹤0.01%	867
2024 Q1	$119	Hold	7	–	–	﹤0.01%	779
2023 Q4	$71	Hold	7	–	–	﹤0.01%	859
2023 Q3	$132	Hold	7	–	–	﹤0.01%	823
2023 Q2	$510	Hold	7	–	–	﹤0.01%	767
2023 Q1	$630	Hold	7	–	–	﹤0.01%	705
2022 Q4	$649	Hold	7	–	–	﹤0.01%	693
2022 Q3	$2K	Hold	7	–	–	﹤0.01%	642
2022 Q2	$1K	Hold	7	–	–	﹤0.01%	741
2022 Q1	$1K	Hold	7	–	–	﹤0.01%	695
2021 Q4	$1K	Hold	7	–	–	﹤0.01%	738
2021 Q3	$2K	Buy	+7	New	+$2.14K	﹤0.01%	664
2020 Q1	–	Sell	-7	Closed	-$4K	–	528
2019 Q4	$4K	Buy	+7	New	+$4.82K	﹤0.01%	581

Other funds holding TCRT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

PSI Advisors's TCRT Position: Q2 2025 in Review

PSI Advisors sold out of Alaunos Therapeutics (TCRT) in Q2 2025, closing a stake of 6 shares — an estimated $9 sold.

PSI Advisors first reported a position in TCRT in Q4 2019 and held it in 16 quarters. The position peaked at $4K in Q4 2019. 28 funds tracked by Wall St. Rank hold TCRT as of Q2 2025.

PSI Advisors reported no remaining Alaunos Therapeutics position as of Q2 2025 after selling out during the quarter.
PSI Advisors sold 6 Alaunos Therapeutics shares in Q2 2025, an estimated $9.
PSI Advisors first reported a position in Alaunos Therapeutics in Q4 2019 and held it in 16 quarters.
PSI Advisors's Alaunos Therapeutics position peaked at $4K in Q4 2019.
28 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2025.

Based on PSI Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.